Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation

Oncogene

Volumn 16, Issue 18, 1998, Pages 2345-2349

  Houldsworth, Jane ^a   Xiao, Han ^a   Murty, V V V S ^a,b   Chen, Weiyi ^a   Ray, Beevash ^a   Reuter, Victor E ^a   Bosl, George J ^a   Chaganti, R S K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Surgeons of Columbia University ^*  (United States)

Author keywords

Germ cell tumor; Mutation; Resistance; TP53

Indexed keywords

CISPLATIN; MESSENGER RNA; PROTEIN BAX; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; GENE EXPRESSION; GENE INDUCTION; GENE MUTATION; GERM CELL TUMOR; HUMAN; HUMAN CELL; MALE; ONCOGENE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0032493125     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1201770     Document Type: Article

References (23)

1. Barak Y, Juven T, Haffner R and Oren M. (1993). EMBO J., 12, 461-468.
2. Bartkova J, Bartek J, Lukas J, Vojtesek B, Staskova Z, Rejthar A, Kovarik J, Midgley CC and Lane DP. (1991). Int. J. Cancer, 49, 196-202.
3. Bosl GJ, Bajorin D, Sheinfeld J and Motzer R. (1997). Cancer: Principles and Practice of Oncology (5th ed). De Vita VT, Hellman S and Rosenberg S (eds). JB Lippincott Co: Philadelphia.
4. Canman CE, Gilmer TM, Coutts SB and Kastan MB. (1995). Genes Develop., 9, 600-611.
5. Chaganti RSK, Murty VVVS and Bosl GJ. (1996). Comprehensive Textbook of Genitourinary Oncology. Vogelzang NJ, Shipley WU, Scardino PT and Coffey DS (eds). Williams and Wilkins: Baltimore, pp. 932-940.
6. Chresta CM, Masters JRW and Hickman JA. (1996). Cancer Res., 56, 1834-1841.
7. El-Diery WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B. (1993). Cell, 75, 817-825.
8. Harris CC. (1996). Carcinogenesis, 17, 1187-1198.
9. Harris CC and Hollstein M. (1993). N. Engl. J. Med., 329, 1318-1327.
10. Heimdal K, Lothe RA, Lystad S, Holm R, Fossa SD and Borresen AL. (1993). Genes Chromo. Cancer, 6, 92-97.
11. Houldsworth J, Reuter VE, Bosl GJ and Chaganti RSK. (1997). Cell Growth Differ., 8, 293-299.
12. Ko LJ and Prives C. (1996). Genes Develop., 10, 1054-1072.
13. Levine AJ. (1997). Cell, 88, 323-331.
14. Lutzker SG and Levine AJ. (1996). Nature Med., 2, 804-810.
15. Miyashita T and Reed JC. (1995). Cell, 80, 293-299.
16. Peng H, Hogg D, Malkin D, Bailey D, Gallie BL, Bulbul M, Jewett M, Buchanan J and Goss PE. (1993). Cancer Res., 53, 3574-3578.
17. Polyak K, Waldman T, He TC, Kinzler KW and Vogelstein B. (1996). Genes Develop., 10, 1945-1952.
18. Riou G, Barrois M, Prost S, Terrier MJ, Theodore C and Levine AJ. (1995). Mol. Carcinogenesis, 12, 124-131.
19. Schwanz D, Goldfinger N and Rotter V. (1993). Oncogene, 8, 1487-1494.
20. Ulbright TM. (1993). Am. J. Surg. Pathol. 17, 1075-1091.
21. White E. (1996). Genes Develop., 10, 1-15.
22. Xu L, Davidson BJ, Murty VVVS, Li RG, Sacks PG, Garin-Chesa P, Schantz SP and Chaganti RSK. (1994). Int. J. Cancer, 59, 383-387.
23. Yang E and Korsmeyer SJ. (1996). Blood, 88, 386-401.